Many novice investors evaluating a pharmaceutical company tend to focus first on themes, positive catalysts, market热度, and stock price levels, leaving fundamental risk assessment for last. However, in the highly volatile innovative drug sector, identifying red flags must always take precedence over stock selection. No matter how promising the track or pipeline, if a company's operational foundation is unstable, all growth expectations can collapse. This guide provides a safety assessment framework for pharmaceutical stocks that doesn't require complex expertise, helping newcomers spot potential structural risks and make more prudent decisions.

Core Metric to Watch: Cash Reserves—The Lifeline of Biotech Operations

For innovative biotech companies that have yet to achieve profitability, all positive catalysts, pipelines, and themes are variables—cash reserves are the most tangible operational safeguard. Without sufficient cash, research cannot advance, clinical trials cannot proceed, and day-to-day operations come under pressure. The company may ultimately be forced to raise capital at depressed valuations, diluting existing shareholders' equity.

1) Evaluating Three Key Fundamental Data Points (Directly from Financial Reports)

(1) Monetary funds plus trading financial assets: This represents the company's currently available discretionary cash—its true financial foundation. Be sure to exclude restricted deposits and cash, and also watch for short-term debt that might require immediate repayment. (2) Operating expenditures over the past 12 months. These can be divided into two categories. For non-profitable biotech companies: R&D expenses plus operating expenses (primarily administrative costs; marketing spend may only become significant once a commercial product exists, so it can be considered on a case-by-case basis—if the company has no innovative drugs and minimal commercial activity, it can be ignored). This represents the company's total cash burn over the last 12 months—that is, excluding BD (business development) income and product sales revenue, since many clinical-stage biopharmaceutical companies have no such income yet. For biotech companies that already have commercialized products or BD income: use net cash outflow from operating activities. If the latest data comes from a quarterly or interim report, review past quarterly, annual, and interim reports to calculate the last 12 months of operating expenses ending at the most recent reporting period. For example, with a 2026 interim report, use the 2026 H1 data plus the 2025 annual report minus the 2025 H1 data; with a 2026 Q3 report, sum the first three quarters of 2026 plus Q4 of 2025, and so on. (3) Cash coverage period: Available cash (1) divided by the company's net expenditure over the past 12 months (2). This indicates how long the company can sustain operations without external financing.

2) A Safe Zone Reference for Beginners

A cash coverage period of at least 24 months can serve as a reference threshold for novice biotech investors. This means the company's cash reserves can support over two years of R&D operations, giving it ample time to await clinical data readouts, BD payments, or product launches—with a very high margin for error. For example, 映恩生物 (09606.HK), which has yet to commercialize a product, held approximately RMB 3.374 billion in cash, deposits, and financial assets at the end of 2025, while its combined R&D and administrative expenses for 2025 were about RMB 1.052 billion. Based on its cash and deposit position, it should be able to support at least two years of operations. 云顶新耀 (01952.HK), which recently surged on the back of Moderna (MRNA.US), only shed its "B" designation last year. As of June 30, 2026, its cash and cash equivalents, bank deposits, and financial assets at fair value through profit or loss totaled approximately RMB 2.036 billion. Its net operating cash outflow for H1 2026 was RMB 273 million, and adding the net operating cash inflow of approximately RMB 88.91 million from H2 2025 (2025 full-year data minus 2025 H1 data), the 12-month net operating cash outflow as of June 30, 2026, may be around RMB 184 million. Given its cash, deposit, and short-term investment scale, this should be sufficient to cover net operating cash outflows. For additional prudence, review its recent expenses: based on 云顶新耀's financial data, the 12-month R&D and administrative expenses as of June 30, 2026, are estimated at about RMB 886 million—roughly 43.5% of its cash and short-term investments as of the end of June 2026.

3) High-Risk Avoidance Criteria

If the cash coverage period is less than 12 months, and there is no imminent large-scale BD deal, no NDA-stage or already-approved commercial product, and no clear financing plan or bank credit facility, these stocks warrant heightened caution: no matter how impressive the pipeline, if cash is running dry and there is no bank credit line, the company will likely resort to frequent equity financing at depressed prices, significantly diluting existing shareholders and keeping the stock price under persistent pressure. For mature pharmaceutical companies that are already consistently profitable, a strict cash coverage calculation may not be necessary, but it is essential to verify that operating cash flow remains positive. If a mature pharma company has negative net operating cash flow for several consecutive years, it may signal deteriorating commercialization capability and operational strain, leading to a long-term decline in valuation—another reason to avoid such stocks.

Due Diligence Red Flags: Equity Structure and Team Risks

Cash is the baseline for survival, while equity structure and team stability are the foundation for long-term growth. Two hidden risks often lie at the core of prolonged stock declines.

1) Frequent and Substantial Equity Dilution

A company that regularly issues new shares, placements, or convertible bonds—where the proceeds are used solely to stay afloat rather than to advance core pipeline R&D—poses a clear risk. Continuous dilution directly erodes shareholder equity, and even if the pipeline eventually delivers value, ordinary investors may struggle to profit. A pattern of long-term stock price volatility and gradual decline is common in such cases. Hong Kong stock screening: visit the HKEX "披露易" website, search company announcements, and filter for keywords such as "placement" or "issue of new shares under general mandate." Alternatively, use data terminals like Wind to track the target company's capital-raising activities. If there have been two or more large equity financings in the past 12 months (placements or new share issues of 10% or more, with an issue price representing a double-digit deep discount to the pre-announcement share price), and the company remains in a state of sustained losses, this may be treated as a high-risk signal.

2) Persistent Insider Selling by Senior Management and Core Personnel

Executives and core technical teams are the ones who know the company's true situation best. If there are frequent large-scale reductions by key personnel, mass resignations, or attrition in the R&D team, it may signal internal doubts about the pipeline's prospects or the company's operating conditions—an extremely strong negative signal that should be avoided. Hong Kong stock screening: again, use "披露易" to search for "directors' interests changes" announcements or personnel "changes," focusing on shareholding movements of the CEO, CSO (Chief Scientific Officer), VP of R&D, and other core roles. If cumulative reductions exceed 20% of their holdings within the past 6 months, or if multiple core R&D personnel resign or reduce holdings simultaneously, this may be considered a negative signal.

Policy and Track Red Flags: Identifying Structural Risks

Biopharmaceuticals operate in a heavily regulated policy environment, where policy risk is systemic and individual companies struggle to buck the trend. Beginners should proactively avoid two types of policy-high-risk targets.

1) Heavy Reliance on Centralized Procurement (VBP) for Generic/Me-too Drugs

Ordinary generics, me-too drugs without clear clinical advantages, and biosimilars—where the core market depends entirely on domestic health insurance procurement—face direct margin compression from routine VBP price cuts. However, this is not a blanket rule. Among generic drugmakers, the following characteristics may still indicate investment value: (1) integrated API-to-formulation capabilities with a strong cost barrier, allowing for volume-for-price trade-offs under VBP while maintaining healthy cash flow; (2) a focus on complex formulations (liposomes, microspheres, inhalation agents, etc.) with higher technical barriers and a more favorable competitive landscape; (3) an active pivot toward high-barrier generics or innovative drugs, with a clear pipeline ladder and potential for product succession. Hong Kong stock screening: review financial reports to map whether core products are included in VBP or national health insurance negotiations. If core products accounting for more than 30% of total revenue are hit by policy-driven price cuts, accompanied by a sustained decline in gross margin, weakening adjusted net profit margins (often reported as non-IFRS or adjusted net profit), deteriorating operating cash flow, and a lack of offsetting capabilities in cost, technology, or differentiated pipeline, these stocks warrant key avoidance. Note: a decline in gross margin for VBP-winning companies is a common industry phenomenon and should not be used as the sole avoidance criterion. Some companies abandon the hospital VBP market in favor of out-of-hospital channels, and "VBP" keywords may not frequently appear in financial reports—cross-validate with business segments and product sales structure.

2) Core Products Facing Patent Cliff Risk

When the patent protection for a company's primary revenue-generating product is nearing expiration, and there is no new pipeline ready to take over, the risk is significant. After patent expiry, a wave of generic applications floods the market, pressuring the original product's pricing and market share, leading to a decline in company performance. Hong Kong stock screening: examine annual report patent disclosures and IP announcements, focusing on the expiry dates of compound patents for core products in China, while also considering derivative patents (crystal forms, formulations, uses). If the overall patent protection window for the core product is within 2-3 years, and the pipeline lacks NDA or Phase III successor candidates, with no high-certainty BD compensation, be wary of downward earnings pressure. Note: the market often prices in expectations well before the actual patent expiry. For License-in products, patent ownership does not belong to the listed company, and annual report patent sections may be limited—rely on licensing agreements for judgment, not just the annual report patent chapter.

Summary

The first priority in pharmaceutical investing is not chasing big winners but learning to avoid 99% of the pitfalls. Surviving longer matters more than getting rich quickly. Before making any decision, run this framework as a filter—if it doesn't pass the screen, don't act.